EPCORE: Epcoritamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Sponsor: AbbVie Inc.
Full Title
Protocol M23-362: A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting
Study Treatment
Subcutaneously administered CD20xCD3 bispecific antibody Epcoritamab
Eligibility/Info
- Diffuse Large B-Cell Lymphoma after at least 1 prior line of therapy that included an anti-CD20 monoclonal antibody
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
